1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Market Spotlight: Coronary Artery Disease

Market Spotlight: Coronary Artery Disease

  • October 2019
  • 47 pages
  • ID: 5780094
  • Format: PDF
  • By Pharma Intelligence

Summary

Table of Contents

Coronary artery disease (CAD), also called ischemic heart disease, occurs due to the narrowing of coronary arteries that supply oxygen-rich blood to the heart. A waxy substance called plaque builds up inside these arteries, leading to atherosclerosis. Plaque builds up within the coronary artery walls until the flow of oxygen-rich blood to the heart muscle is limited. This condition is also called ischemia, which may be chronic or acute. In chronic ischemia, the coronary artery narrows over time, limiting the blood flow to part of the heart muscle, while acute ischemia occurs due to a sudden rupture of plaque and formation of a blood clot. These blood clots can completely or mostly block the flow of blood through the artery, leading to acute myocardial ischemia, which further results in acute coronary syndromes. These include unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation MI (STEMI). If the oxygen-rich blood flow to the heart is blocked or reduced, heart attack or angina can occur.

Key Takeaways
The analyst estimates that in 2017, there were approximately 327.9 million prevalent cases of coronary artery disease worldwide, and forecasts that number to increase to 365.9 million prevalent cases by 2026.
Coronary artery disease has a male predominance. Globally, the analyst estimates that in 2017, 58.65% of cases aged 15 years and over were male.
The analyst estimates that in 2017, there were approximately 9.5 million incident cases of acute coronary syndrome worldwide, and forecasts that number to increase to 10.7 million incident cases by 2026.
Acute coronary syndrome has a male predominance. Globally, the analyst estimates that in 2017, 63.78% of cases aged 25 years and over were male.
The approved drugs in the coronary artery disease space target angiotensin converting enzyme, amyloid beta/amyloid plaques, calcium channel, and coagulation factor X. The majority of marketed drugs are administered via the oral route, with one product being available in an intravenous formulation.
The majority of industry-sponsored drugs in active clinical development for coronary artery disease are in Phase II. Therapies in development for coronary artery disease focus on a wide variety of targets. These drugs are administered via the oral, intravenous, and percutaneous catheter/injection routes.
The overall likelihood of approval of a Phase I cardiovascular disease asset is 6.9%, and the average probability a drug advances from Phase III is 53.5%. Drugs, on average, take 9.8 years from Phase I to approval in the overall cardiovascular space.
There have been 12 licensing and asset acquisition deals involving coronary artery disease drugs during 2014–19. The definitive license agreement signed in 2017 between Lantheus and GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational PET MPI agent, for $65m was the largest deal.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for coronary artery disease have been in the late phases of development, with 52% of trials in Phase III–IV, and 48% in Phase I–II.
The US has a substantial lead in the number of coronary artery disease clinical trials globally. Germany leads the major EU markets, while China has the top spot in Asia.
Clinical trial activity in the coronary artery disease space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for coronary artery disease, with 96 trials.
Pfizer leads industry sponsors with the highest number of clinical trials for coronary artery disease

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) ...

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’A Disintegrin And Metalloproteinase With Thrombospondin Motifs ...

Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019

Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019, provides an overview of the ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on